# US 2012/0252872 A1 · RNAi Modulation of APOB and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252872 A1
- Document ID: US20120252872A1
- Status: Published application
- Kind: A1
- Application number: 13/450,886
- Filed: 2012-04-19
- Published: 2012-10-04
- Earliest claimed: 2004-09-24
- Assignees: Alnylam Pharmaceuticals, Inc.
- Inventors: Juergen Soutschek; Hans-Peter Vornlocher; Philipp Hadwiger; Sayda Elbashir
- Web page: https://patentgrep.com/patent/US20120252872A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/718: Starch or degraded starch, e.g. amylose, amylopectin
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.

## Claims

### Claim 1

An iRNA agent comprising a sense strand and an antisense strand, wherein said sense strand comprises a first sequence and said antisense strand comprises a second sequence, wherein said first sequence is complementary to said second sequence, wherein said first sequence is complementary to a segment of an Apolipoprotein B (ApoB) mRNA, and wherein each strand of said iRNA agent is between 15 and 30 base pairs in length.

### Claim 2 (depends on 1)

The iRNA agent of claim 1, further comprising a non-nucleotide moiety.

### Claim 3 (depends on 1)

The iRNA agent of claim 1, further comprising a phosphorothioate linkage.

### Claim 4 (depends on 3)

The iRNA agent of claim 3, wherein said iRNA agent comprises a phosphorothioate at the first and second internucleotide linkage at the 3′ end of the antisense strand.

### Claim 5 (depends on 3)

The iRNA agent of claim 3, wherein said iRNA agent comprises a phosphorothioate at the first internucleotide linkage at the 3′ end of the sense strand.

### Claim 6 (depends on 1)

The iRNA agent of claim 1, further comprising a 2′-modified nucleotide.

### Claim 7 (depends on 6)

The iRNA agent of claim 6, wherein the 2′-modification is chosen from the group of: 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), and 2′-O—N-methylacetamido (2′-O-NMA).

### Claim 8 (depends on 6)

The iRNA agent of claim 6, further comprising: at least one 5′-uridine-adenine-3′ (5′-UA-3′) dinucleotide wherein the uridine is a 2′-modified nucleotide; at least one 5′-uridine-guanine-3′ (5′-UG-3′) dinucleotide, wherein the 5′-uridine is a 2′-modified nucleotide; at least one 5′-cytidine-adenine-3′ (5′-CA-3′) dinucleotide, wherein the 5′-cytidine is a 2′-modified nucleotide; or at least one 5′-uridine-uridine-3′ (5′-UU-3′) dinucleotide, wherein the 5′-uridine is a 2′-modified nucleotide.

### Claim 9 (depends on 8)

The iRNA agent of claim 8, wherein the 5′-most pyrimidines in all occurrences of sequence motif 5′-UA-3′, 5′-CA-3′, 5′-UU-3′, and 5′-UG-3′ on the antisense strand are 2′-modified nucleotides.

### Claim 10 (depends on 1)

The iRNA agent of claim 1, wherein the first sequence is selected from the sense strand sequences shown in Tables 1, 3, 10, or 11.

### Claim 11 (depends on 1)

The iRNA agent of claim 1, wherein the second sequence is selected from the antisense strand sequences shown in Tables 1, 3, 10, or 11.

### Claim 12 (depends on 1)

The iRNA agent of claim 1, wherein a 5′-end of said iRNA agent comprises an adenosine, cytidine, guanosine, thymidine, or uridine.

### Claim 13 (depends on 1)

The iRNA agent of claim 1, further comprising a nucleotide overhang having 1 to 4 nucleotides.

### Claim 14 (depends on 13)

The iRNA agent of claim 13, wherein the nucleotide overhang has 2 or 3 unpaired nucleotides.

### Claim 15 (depends on 13)

The iRNA agent of claim 13, wherein the nucleotide overhang is at the 3′-end of the antisense strand of the iRNA agent.

### Claim 16 (depends on 1)

The iRNA agent of claim 1, further comprising a cholesterol moiety.

### Claim 17 (depends on 16)

The iRNA agent of claim 16, wherein the cholesterol moiety is conjugated to the 3′-end of the sense strand of the iRNA agent.

### Claim 18 (depends on 1)

The iRNA agent of claim 1, wherein said iRNA agent reduces the amount of ApoB mRNA present in cultured mouse cells of hepatic origin by an amount greater than a control iRNA agent.

### Claim 19 (depends on 1)

The iRNA agent of claim 1, wherein the agent reduces the amount of ApoB mRNA in cultured human HepG2 cells after incubation with the agent by more than 50% compared to cells that have not been incubated with the agent, or reduces the amount of ApoB protein secreted into cell culture supernatant by more than 50% compared to a control.

### Claim 20 (depends on 1)

A method for reducing the expression levels of ApoB in a subject, further comprising the step of administering the iRNA agent of claim 1 to said subject.
